Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma

Journal of Surgical Oncology

Volumn 95, Issue 4, 2007, Pages 317-323

  Kwak, Cheol ^a   Park, Yong Hyun ^a   Jeong, Chang Wook ^a   Jeong, Hyeon ^b   Lee, Sang Eun ^b   Moon, Kyung Chul ^a   Ku, Ja Hyeon ^c  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul Veterans Hospital   (South Korea)

Author keywords

Immunotherapy; Metastasis; Prognosis; Renal cell carcinoma; Sarcomatoid

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SARCOMA; TUMOR DIFFERENTIATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL DIFFERENTIATION; COHORT STUDIES; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; SARCOMA; SURVIVAL RATE; TIME FACTORS;

EID: 33847682904     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20669     Document Type: Article

References (24)

1. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, et al.: Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy. J Clin Oncol 1994;12: 206-212.
2. Robson CJ, Churchill BM, Anderson W: The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
3. de Peralta-Venturina M, Moch H, Amin M, et al.: Sarcomatoid differentiation in renal cell carcinoma: A study of 101 cases. Am J Surg Pathol 2001;25:275-284.
4. Delahunt B: Sarcomatoid renal carcinoma: The final common dedifferentiation pathway of renal epithelial malignancies. Pathology 1999;31:185-190.
5. Akhtar M, Tulbah A, Kardar AH, et al.: Sarcomatoid renal cell carcinoma: The chromophobe connection. Am J Surg Pathol 1997;21:1188-1195.
6. Farrow OM, Harrison EG Jr, Utz DC: Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. Part III. Cancer 1968;22:556-563.
7. Tomera KM, Farrow OM, Lieber MM: Sarcomatoid renal carcinoma. J Urol 1983;130:657-659.
8. Bertoni F, Ferri C, Benati A, et al.: Sarcomatoid carcinoma of the kidney. J Urol 1987;137:25-28.
9. Ro JY, Ayala AG, Sella A, et al.: Sarcomatoid renal cell carcinoma: Clinicopathologic. A study of 42 cases. Cancer 1987; 59:516-526.
10. Cheville JC, Lohse CM, Zincke H, et al.: Sarcomatoid renal cell carcinoma: An examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 2004;28:435-441.
11. Cangiano T, Liao J, Naitoh J, et al.: Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 1999;17:523-528.
12. Mian BM, Bhadkamkar N, Slaton JW, et al.: Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002;167:65-70.
13. Sella A, Logothetis CJ, Ro JY, et al.: Sarcomatoid renal cell carcinoma. A treatable entity. Cancer 1987;60:1313-1318.
14. Culine S, Bekradda M, Terrier-Lacombe MJ, et al.: Treatment of sarcomatoid renal cell carcinoma: Is there a role for chemotherapy? Eur Urol 1995;27:138-141.
15. Atkins MB, Regan M, McDermott D: Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10:6342S-6636S.
16. Pyrhonen S, Salminen E, Ruutu M, et al.: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17: 2859-2867.
17. Medical Research Council Renal Cancer Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet 1999;353:14-17.
18. Atzpodien J, Kirchner H, Hanninen EL, et al.: Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993;29A:S6-S8.
19. Atzpodien J, Hoffmann R, Franzke M, et al.: Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 2002;95:1045-1050.
20. van Herpen CM, Jansen RL, Kruit WH, et al.: Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: A multicenter phase II study. Dutch Immunotherapy Working Party. Br J Cancer 2000;82:772-776.
21. Elias L, Lew D, Figlin RA, et al.: Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma. Cancer 2000;89: 597-603.
22. Kozlowski JM: Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites. Urol Clin North Am 1994;21:601-624.
23. van der Poel HO, Roukema JA, Horenblas S, et al.: Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. Eur Urol 1999;35:197-203.
24. Kavolius JP, Mastorakos DP, Pavlovich C, et al.: Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261-2266.